Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease — Is It Time to Shift Our Goals?
- 7 April 2005
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (14) , 1483-1484
- https://doi.org/10.1056/nejme058052
Abstract
The evidence of the effectiveness of statins in the treatment of stable coronary heart disease (CHD) continues to grow. Large-scale, randomized, secondary-prevention trials involving patients with CHD have shown that statins reduce the clinical consequences of atherosclerosis, including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina pectoris and heart failure, as well as the need for coronary revascularization. Current guidelines recommend a low-density lipoprotein (LDL) cholesterol level of less than 100 mg per deciliter (2.6 mmol per liter) as the goal for patients with stable CHD and a goal of 70 mg per deciliter (1.8 . . .Keywords
This publication has 6 references indexed in Scilit:
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption InhibitorCardiovascular Drug Reviews, 2003
- High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective studyPublished by Elsevier ,2001